Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
24/03/2026 11:11
March 24 (Reuters) - Karyopharm Therapeutics KPTI.O said on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a late‑stage trial in patients with a rare blood cancer, one of the study's main goals. However, the drug missed the other goal of showing an improvement in patients' symptoms. (Reporting by Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview